Prothena Corp Plc (PRTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Prothena Corp Plc (PRTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8271
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prothena Corp Plc (Prothena) is a clinical biotechnology company, which discovers, develops and markets novel medicines that are indicated for the treatment of diseases associated with neuroscience and orphan diseases. The company develops monoclonal antibodies directed specifically at disease-causing proteins. Its pipeline products include PRX002, that targets alpha -synuclein protein for the treatment of Parkinson’s disease and other synucleinopathies; NEOD001, that targets the circulating soluble and deposited aggregated amyloid in the treatment of primary systemic amyloidosis; PRX004, indicated to clear the misfolded (toxic) forms of the TTR amyloid protein in Transthyretin amyloidosis (ATTR amyloidosis). Protena also develops several discovery-stage programs in collaboration with other pharmaceurtical companies for neurodegenerative or orphan diseases such as Alzheimer’s disease (AD), ALECT2 amyloidosis, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Prothena is headquartered in Dublin, Ireland.

Prothena Corp Plc (PRTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 12
MJFF Enters into Agreement with Prothena 14
Licensing Agreements 15
Roche Enters Into Licensing Agreement With Prothena 15
Equity Offering 17
Prothena Files Registration Statement for Public Offering of Shares 17
Prothena Raises USD155.3 Million in Public Offering of Shares 18
Prothena Raises USD137 Million in Public Offering of Shares 20
Prothena Raises USD122 Million in Public Offering of Shares 22
Prothena Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD123 Million 24
Prothena Raises USD82.7 Million in Public Offering of Shares 26
Prothena Completes Public Offering Of Shares For US$92 Million 28
Prothena Corp Plc – Key Competitors 30
Prothena Corp Plc – Key Employees 31
Prothena Corp Plc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Strategy And Business Planning 33
May 24, 2018: Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline 33
Financial Announcements 34
Aug 07, 2018: Prothena reports second quarter 2018 financial results and provides R&D update 34
May 08, 2018: Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update 36
Feb 14, 2018: Prothena Reports Fourth Quarter and Full Year 2017 Financial Results 38
Nov 07, 2017: Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update 40
Aug 08, 2017: Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update 42
May 09, 2017: Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update 44
Feb 14, 2017: Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update 46
Corporate Communications 48
Jun 25, 2018: Prothena Appoints Tran B. Nguyen As Chief Operating Officer 48
Feb 02, 2018: Prothena Announces Resignation of Sarah Noonberg As Chief Medical Officer 49
Jun 12, 2017: Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer 50
May 16, 2017: Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer 51
Clinical Trials 52
Jun 19, 2018: Prothena Announces Phase 1b Clinical Trial Results Of PRX002/RG7935 For Parkinson’s Disease Published In JAMA Neurology 52
Jun 18, 2018: New immunotherapy could stop progression of Parkinson’s disease 53
Sep 18, 2017: Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis 54
Aug 15, 2017: Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting 56
Jul 05, 2017: Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease 57
Jun 08, 2017: Anti-Alpha-Synuclein Antibody is a Potential Disease-Modifying Treatment for Parkinson’s Disease 58
Apr 02, 2017: Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease 59
Mar 09, 2017: Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson’s Disease to be Presented at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases 61
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Prothena Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 12
MJFF Enters into Agreement with Prothena 14
Roche Enters Into Licensing Agreement With Prothena 15
Prothena Files Registration Statement for Public Offering of Shares 17
Prothena Raises USD155.3 Million in Public Offering of Shares 18
Prothena Raises USD137 Million in Public Offering of Shares 20
Prothena Raises USD122 Million in Public Offering of Shares 22
Prothena Completes Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD123 Million 24
Prothena Raises USD82.7 Million in Public Offering of Shares 26
Prothena Completes Public Offering Of Shares For US$92 Million 28
Prothena Corp Plc, Key Competitors 30
Prothena Corp Plc, Key Employees 31
Prothena Corp Plc, Subsidiaries 32

List of Figures
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Prothena Corp Plc (PRTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • First Solar Inc (FSLR):企業の財務・戦略的SWOT分析
    First Solar Inc (FSLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Pt Indofood Sukses Makmur Tbk
    Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Charles River Laboratories International Inc (CRL):製薬・医療:M&Aディール及び事業提携情報
    Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. Th …
  • Flowers Foods Inc:戦略・SWOT・企業財務分析
    Flowers Foods Inc - Strategy, SWOT and Corporate Finance Report Summary Flowers Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Hansol Logistics Co., Ltd. (009180):企業の財務・戦略的SWOT分析
    Hansol Logistics Co., Ltd. (009180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Orsted AS Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Orsted AS Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Orsted AS (Orsted) formerly Dong Energy A/S, is an integrated energy company that procures, produces, distributes and trades energy and energy related products. It generates electricity and heat using conv …
  • Iberdrola SA (IBE):電力:M&Aディール及び事業提携情報
    Summary Iberdrola SA (Iberdrola) is an energy utility. It constructs, operates, and manages power generation plants, transmission and distribution facilities, and other assets. The company produces electricity using conventional and renewable energy sources. Iberdrola also trades electricity and gas …
  • Rompetrol Rafinare SA (RRC):企業の財務・戦略的SWOT分析
    Rompetrol Rafinare SA (RRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Laissez-Faire Catering Pty Ltd
    Laissez-Faire Catering Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Laissez-Faire Catering Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Exiqon AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Exiqon AS (Exiqon), a subsidiary of Qiagen NV, is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company provides product categories such as microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reag …
  • Telkom SA SOC Limited:企業の戦略・SWOT・財務情報
    Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Workday, Inc.:企業のM&A・事業提携・投資動向
    Workday, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Workday, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Genera Biosystems Ltd (GBI):製薬・医療:M&Aディール及び事業提携情報
    Summary Genera Biosystems Ltd (GBL) is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is …
  • Omnicom Group, Inc.:企業の戦略・SWOT・財務分析
    Omnicom Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Omnicom Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Petro-Victory Energy Corp (VRY):石油・ガス:M&Aディール及び事業提携情報
    Summary Petro-Victory Energy Corp (Petro-Victory) is an oil and gas company that provides exploration and production of hydrocarbon, oil and natural gas resources. The company provides onshore exploration to identify prospective resources, promote and initiate drilling campaigns to find hydrocarbon …
  • Icelandair Group:戦略・SWOT・企業財務分析
    Icelandair Group - Strategy, SWOT and Corporate Finance Report Summary Icelandair Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • FLIR Systems Inc:企業のM&A・事業提携・投資動向
    FLIR Systems Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's FLIR Systems Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • U-Shin Ltd.:企業の戦略的SWOT分析
    U-Shin Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Tosoh Bioscience Inc:企業の製品パイプライン分析2018
    Summary Tosoh Bioscience Inc (TBI), a subsidiary of Tosoh Corp, is a medical device company that offers diagnostic systems. The company provides analyzers, assays, immunoassay solutions, reagent technology, HbA1c solutions, ß-thalassemia testing, and HPLC technology. Its immunoassay solutions compri …
  • Tree Top, Inc.:企業の戦略・SWOT・財務分析
    Tree Top, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tree Top, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆